Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Core Insights - Can-Fite BioPharma Ltd. is collaborating with Vetbiolix to advance the clinical study of Piclidenoson for treating osteoarthritis in dogs, with projected revenues of $325 million over the next decade upon regulatory approval [1][2][4] Company Overview - Can-Fite BioPharma Ltd. is a biotechnology company focused on developing small molecule drugs for oncological and inflammatory diseases, with a lead drug candidate Piclidenoson showing promise in both human and animal studies [1][7] - The company has a pipeline that includes drugs for various conditions, including cancer and liver diseases, with ongoing clinical trials for its lead candidates [7][8] Market Opportunity - The arthritis market for companion animals is valued at $3.8 billion in 2023 and is expected to grow to $6.3 billion by 2030, with Piclidenoson potentially capturing up to 6% of this market, leading to peak sales of $445 million by 2034 [2][4] - Can-Fite is entitled to a 15% royalty on worldwide sales of Piclidenoson in this indication, indicating a significant revenue potential for the company [2][4] Product Development - Current treatments for canine osteoarthritis are limited and often come with significant side effects, while Piclidenoson offers a safer and potentially more effective oral treatment option [3][5] - Vetbiolix has successfully completed a clinical study for Piclidenoson, which supports its pharmacological profile as a viable treatment for osteoarthritis in pets [2][5] Strategic Partnerships - The collaboration with Vetbiolix is aimed at leveraging the veterinary market, which presents shorter timelines for regulatory approval compared to human medicine, thus enhancing revenue opportunities for Can-Fite [4][6]